Analysis of histopathologic and molecular pathologic findings in Czech LGMD2A patients

被引:33
作者
Hermanová, M
Zapletalová, E
Sedlácková, J
Chrobáková, T
Letocha, O
Kroupová, I
Zámecník, J
Vondrácek, P
Mazanec, R
Maríková, T
Vohánka, S
Fajkusová, L
机构
[1] Univ Hosp Brno, Dept Pathol, Brno 62500, Czech Republic
[2] Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, Brno 62500, Czech Republic
[3] Masaryk Univ, CS-60177 Brno, Czech Republic
[4] Univ Hosp Motol, Dept Pathol & Mol Med, Prague, Czech Republic
[5] Univ Hosp Brno, Dept Child Neurol, Brno 62500, Czech Republic
[6] Univ Hosp Motol, Dept Neurol, Prague, Czech Republic
[7] Univ Hosp Motol, Inst Biol & Med Genet, Fac Med 2, Prague, Czech Republic
[8] Univ Hosp Brno, Dept Neurol, Brno 62500, Czech Republic
关键词
LGMD2A; muscle biopsy; mutational analysis; neurogenic pattern;
D O I
10.1002/mus.20480
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Limb-girdle muscular dystrophy type 2A (LGMD2A) is an autosomal-recessive disorder characterized by selective atrophy and progressive weakness of proximal girdle muscles. LGMD2A, the most prevalent form of LGMD, is caused by mutations in the CAPN3 gene that encodes the skeletal muscle-specific member of the calpain family, calpain-3 (p94). We examined the histopathologic and molecular pathologic findings in 14 Czech LGMD2A patients. Analysis of the CAPN3 gene was performed at the mRNA level, using reverse transcription-polymerase chain reaction (RT-PCR) and sequencing, and/or DNA level, using PCR and denaturing high-performance liquid chromatography (DHPLC). Our results confirm that mutation 550delA is the most frequent CAPN3 defect in Czech LGMD2A patients (9 alleles of 28). Furthermore, we established that, in a patient with the 550delA/R490W genotype, mRNA carrying frameshift mutation 550delA was not detected, probably due to its degradation by nonsense-mediated mRNA decay. In muscle biopsies of two LGMD2A patients, a neurogenic pattern simulating a neurogenic lesion was observed. Immunoblot analysis revealed the deficiency of p94 in all genetically confirmed cases of LGMD2A, and secondary dysferlin deficiency was demonstrated on muscle membranes in 6 patients using immunofluorescence. Thus, we find a combination of DNA and mRNA mutational analysis to be useful in the diagnosis of LGMD2A. Moreover, our study expands the spectrum of calpainopathies to cases that simulate a neurogenic lesion in muscle biopsies, and the knowledge of possible secondary deficiencies of muscular proteins also contributes to a diagnosis of LGMD2A.
引用
收藏
页码:424 / 432
页数:9
相关论文
共 27 条
  • [1] Characterization of monoclonal antibodies to calpain 3 and protein expression in muscle from patients with limb-girdle muscular dystrophy type 2A
    Anderson, LVB
    Davison, K
    Moss, JA
    Richard, I
    Fardeau, M
    Tomé, FMS
    Hübner, C
    Lasa, A
    Colomer, J
    Beckmann, JS
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (04) : 1169 - 1179
  • [2] Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IκBα/NF-κB pathway in limb-girdle muscular dystrophy type 2A
    Baghdiguian, S
    Martin, M
    Richard, I
    Pons, F
    Astier, C
    Bourg, N
    Hay, RT
    Chemaly, R
    Halaby, G
    Loiselet, J
    Anderson, LVB
    de Munain, AL
    Fardeau, M
    Mangeat, P
    Beckmann, JS
    Lefranc, G
    [J]. NATURE MEDICINE, 1999, 5 (05) : 503 - 511
  • [3] BECKMANN JS, 1991, CR ACAD SCI III-VIE, V312, P141
  • [4] Prevalence of the 550delA mutation in calpainopathy (LGMD 2A) in Croatia
    Canki-Klain, N
    Milic, A
    Kovac, B
    Trlaja, A
    Grgicevic, D
    Zurak, N
    Fardeau, M
    Leturcq, F
    Kaplan, JC
    Urtizberea, JA
    Politano, L
    Piluso, G
    Feingold, J
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2004, 125A (02) : 152 - 156
  • [5] Calpain 3 gene mutations: genetic and clinico-pathologic findings in limb-girdle muscular dystrophy
    Chae, J
    Minami, N
    Jin, Y
    Nakagawa, M
    Murayama, K
    Igarashi, F
    Nonaka, I
    [J]. NEUROMUSCULAR DISORDERS, 2001, 11 (6-7) : 547 - 555
  • [6] Mutations in Czech LGMD2A patients revealed by analysis of calpain3 mRNA and their phenotypic outcome
    Chrobáková, T
    Hermanová, M
    Kroupová, I
    Vondrácek, P
    Maríková, T
    Mazanec, R
    Zámecník, J
    Stanek, J
    Havlová, M
    Fajkusová, L
    [J]. NEUROMUSCULAR DISORDERS, 2004, 14 (10) : 659 - 665
  • [7] Clinical variability in calpainopathy: What makes the difference?
    de Paula, F
    Vainzof, M
    Passos-Bueno, MR
    Pavanello, RDM
    Matioli, SR
    Anderson, LVB
    Nigro, V
    Zatz, M
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2002, 10 (12) : 825 - 832
  • [8] Molecular diagnosis in LGMD2A: Mutation analysis or protein testing?
    Fanin, M
    Fulizio, L
    Nascimbeni, AC
    Spinazzi, M
    Piluso, G
    Ventriglia, VM
    Ruzza, G
    Siciliano, G
    Trevisan, CR
    Politano, L
    Nigro, V
    Angelini, C
    [J]. HUMAN MUTATION, 2004, 24 (01) : 52 - 62
  • [9] Loss of calpain-3 autocatalytic activity in LGMD2A patients with normal protein expression
    Fanin, M
    Nascimbeni, AC
    Fulizio, L
    Trevisan, CP
    Meznaric-Petrusa, M
    Angelini, C
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (05) : 1929 - 1936
  • [10] Myopathy with lobulated muscle fibers: evidence for heterogeneous etiology and clinical presentation
    Figarella-Branger, D
    El-Dassouki, M
    Saenz, A
    Cobo, AM
    Malzac, P
    Tong, S
    Cassotte, E
    Azulay, JP
    Pouget, J
    Pellissier, JF
    [J]. NEUROMUSCULAR DISORDERS, 2002, 12 (01) : 4 - 12